Search Medical Condition
Please enter condition
Please choose location
 

Campina Grande Do Sul, Brazil Clinical Trials

A listing of Campina Grande Do Sul, Brazil clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

A Study of Apixaban in Patients With Atrial Fibrillation Not Caused by a Heart Valve Problem Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Patients will be recruited from either inpatient coronary care or general medical units, or recruited from outpatient cardiology offices. Masking Apixaban: Open label. VKA: Open label. Acetylsalicylic acid film coated tablet: Double Blinded. Placebo matching Acetylsalicylic acid film coated tablet: Double Blinded.

Phase

0.0 miles

Learn More »

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

This is an international, multicentre, parallel group, event-driven, randomized, double-blind, placebo-controlled study in patients with chronic heart failure with reduced ejection fraction (HFrEF), evaluating the effect of dapagliflozin versus placebo, given once daily in addition to background regional standard of care therapy, for the prevention of cardiovascular (CV) death or ...

Phase

0.0 miles

Learn More »

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »